Hutchison China Meditech Limited Total Voting Rights (2886Z)

TIDMHCM

RNS Number : 2886Z

Hutchison China Meditech Limited

31 August 2018

Total Voting Rights

London: Friday, August 31, 2018: Hutchison China MediTech Limited ("Chi-Med") (AIM/Nasdaq: HCM) hereby notifies the market that as at August 31, 2018, the issued share capital of Chi-Med consisted of 66,535,683 ordinary shares of US$1.00 each, with each share carrying one right to vote and with no shares held in treasury.

The above figure of 66,535,683 may be used by shareholders as the denominator for the calculations by which they could determine if they are required to notify their interest in, or a change to their interest in, Chi-Med under the Financial Conduct Authority's Disclosure Rules and Transparency Rules.

For illustrative purposes only, the 66,535,683 ordinary shares would be equivalent to 66,535,683 CREST depositary interests (each equating to one ordinary share) which are traded on AIM or, if the CREST depositary interests were converted in their entirety, equivalent to 133,071,366 American depositary shares (each equating to one-half of one ordinary share) which are traded on Nasdaq.

About Chi-Med

Chi-Med is an innovative biopharmaceutical company which researches, develops, manufactures and sells pharmaceuticals and healthcare products. Its Innovation Platform, Hutchison MediPharma Limited, focuses on discovering and developing innovative therapeutics in oncology and autoimmune diseases for the global market. Its Commercial Platform manufactures, markets, and distributes prescription drugs and consumer health products in China.

Chi-Med is majority owned by the multinational conglomerate CK Hutchison Holdings Limited (SEHK: 1). For more information, please visit: www.chi-med.com.

CONTACTS

 
Investor Enquiries 
Mark Lee, Senior Vice President, 
 Corporate Finance & Development       [phone] 
 
U.K. & International Media Enquiries 
Anthony Carlisle,                      [phone] (Mobile) 
 Citigate Dewe Rogerson                 [e-mail] 
 
U.S. Based Media Enquiries 
Brad Miles, Solebury Trout             [phone] (Mobile) 
                                        [e-mail] 
Susan Duffy, Solebury Trout            [phone] (Mobile) 
                                        [e-mail] 
 
Investor Relations 
Xuan Yang, Solebury Trout              [phone] (Mobile) 
                                        [e-mail] 
David Dible,                           [phone] (Mobile) 
 Citigate Dewe Rogerson                 [e-mail] 
 
Panmure Gordon (UK) Limited 
Richard Gray / Andrew Potts            [phone] 
 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

END

TVREAEPEDAKPEFF

(END) Dow Jones Newswires

August 31, 2018 02:00 ET (06:00 GMT)